drugset / Trial / NCT00622193
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
Timeline
- Start
- 2008-03
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anamorelin | Small molecule | 50 mg | — |
| Subject | Anamorelin | Small molecule | 100 mg | — |